The overall goals of this proposal are to evaluate the utility and molecular effects of recombinant IFN-gamma in patients with active tuberculosis.
Project Title:
Longitudinal Studies of HIV-associated Bacterial Pneumonia
Source of Funds:
NIH
Role:
Co-Investigator
The overall goals of this proposal are to understand the epidemiology, longitudinal evolution, and molecular pathogenesis of HIV-associated bacterial pneumonia.
Project Title:
REMox Trial: A randomised placebo-controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months Ethambutol, Isoniazid, Rifampicin and Pyrazinamide followed by four months Isoniazid and Rifampicin) namely
two months Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide followed by two months Moxifloxacin, Isoniazid and Rifampicin and
two months Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide followed by two months Moxifloxacin and Rifampicin for the treatment of adults with pulmonary tuberculosis.
Principal Investigator:
Stephen Gillespie
Source of Funds:
EDCTP, MRC(UK),Global Alliance for TB Drug Development, Roche Pharmaceuticals Ltd.
Role:
Site Principal Investigator
This is a Phase III randomized, double-blind, placebo controlled study to assess the utility of two moxifloxacin treatment shortening regimens in pulmonary tuberculosis.
